Literature DB >> 17880642

Secondary abnormalities of neurotransmitters in infants with neurological disorders.

A García-Cazorla1, M Serrano, B Pérez-Dueñas, V González, A Ormazábal, M Pineda, E Fernández-Alvarez, J M D Campistol, R M D Artuch.   

Abstract

Neurotransmitters are essential in young children for differentiation and neuronal growth of the developing nervous system. We aimed to identify possible factors related to secondary neurotransmitter abnormalities in pediatric patients with neurological disorders. We analyzed cerebrospinal fluid (CSF) and biogenic amine metabolites in 56 infants (33 males, 23 females; mean age 5.8mo [SD 4.1mo] range 1d-1y) with neurological disorders whose aetiology was initially unknown. Patients were classified into three clinical phenotypes: epileptic encephalopathy, severe motor impairment, and non-specific manifestations. All patients showed normal results for screening of inborn errors of metabolism. We report clinical, neuroimaging, and follow-up data. Among the patients studied, 10 had low homovanillic acid (HVA) levels and in four patients, 5-hydroxyindoleacetic acid (5-HIAA) was also reduced. Patients with neonatal onset had significantly lower levels of HVA than a comparison group. HVA deficiency was also associated with severe motor impairment and the final diagnosis related to neurodegenerative disorders. 5-HIAA values tended to be decreased in patients with brain cortical atrophy. The possibility of treating patients with L-Dopa and 5-hydroxytryptophan, in order to improve their neurological function and maturation, may be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880642     DOI: 10.1111/j.1469-8749.2007.00740.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  13 in total

1.  Analysis of synaptic proteins in the cerebrospinal fluid as a new tool in the study of inborn errors of neurotransmission.

Authors:  Sofia T Duarte; Carlos Ortez; Ana Pérez; Rafael Artuch; Angels García-Cazorla
Journal:  J Inherit Metab Dis       Date:  2011-01-13       Impact factor: 4.982

2.  Neurotransmitter abnormalities and response to supplementation in SPG11.

Authors:  Adeline Vanderver; Davide Tonduti; Sarah Auerbach; Johanna L Schmidt; Sumit Parikh; Gordon C Gowans; Kelly E Jackson; Pamela L Brock; Marc Patterson; Michelle Nehrebecky; Rena Godfrey; Wadih M Zein; William Gahl; Camilo Toro
Journal:  Mol Genet Metab       Date:  2012-06-01       Impact factor: 4.797

Review 3.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

4.  Analysis of human cerebrospinal fluid monoamines and their cofactors by HPLC.

Authors:  Marta Batllori; Marta Molero-Luis; Aida Ormazabal; Mercedes Casado; Cristina Sierra; Angels García-Cazorla; Manju Kurian; Simon Pope; Simon J Heales; Rafael Artuch
Journal:  Nat Protoc       Date:  2017-10-19       Impact factor: 13.491

5.  Cerebrospinal fluid monoamines, pterins, and folate in patients with mitochondrial diseases: systematic review and hospital experience.

Authors:  Marta Batllori; Marta Molero-Luis; Aida Ormazabal; Raquel Montero; Cristina Sierra; Antonia Ribes; Julio Montoya; Eduardo Ruiz-Pesini; Mar O'Callaghan; Leticia Pias; Andrés Nascimento; Francesc Palau; Judith Armstrong; Delia Yubero; Juan D Ortigoza-Escobar; Angels García-Cazorla; Rafael Artuch
Journal:  J Inherit Metab Dis       Date:  2018-07-04       Impact factor: 4.982

6.  Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders.

Authors:  Elisa De Grandis; Mercedes Serrano; Belén Pérez-Dueñas; Aida Ormazábal; Raquel Montero; Edvige Veneselli; Mercè Pineda; Verónica González; Francesc Sanmartí; Carmen Fons; Anna Sans; Bru Cormand; Luis Puelles; Antonia Alonso; Jaime Campistol; Rafael Artuch; Angels García-Cazorla
Journal:  J Inherit Metab Dis       Date:  2010-09-18       Impact factor: 4.982

7.  A modern approach to the treatment of mitochondrial disease.

Authors:  Sumit Parikh; Russell Saneto; Marni J Falk; Irina Anselm; Bruce H Cohen; Richard Haas; The Mitochondrial Medicine Society
Journal:  Curr Treat Options Neurol       Date:  2009-11       Impact factor: 3.598

8.  Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation.

Authors:  Christina Lam; Carlos Ferreira; Donna Krasnewich; Camilo Toro; Lea Latham; Wadih M Zein; Tanya Lehky; Carmen Brewer; Eva H Baker; Audrey Thurm; Cristan A Farmer; Sergio D Rosenzweig; Jonathan J Lyons; John M Schreiber; Andrea Gropman; Shilpa Lingala; Marc G Ghany; Beth Solomon; Ellen Macnamara; Mariska Davids; Constantine A Stratakis; Virginia Kimonis; William A Gahl; Lynne Wolfe
Journal:  Genet Med       Date:  2016-07-07       Impact factor: 8.822

9.  Secondary biogenic amine deficiencies: genetic etiology, therapeutic interventions, and clinical effects.

Authors:  Maja Tarailo-Graovac; Gabriella A Horvath; Clara D van Karnebeek; Ingrid Blydt-Hansen; Allison M Matthews; Vladimir Avramovic; Magda Price; Britt Drogemoller; Casper Shyr; Jessica Lee; Jill Mwenifumbo; Aisha Ghani; Sylvia Stockler; Jan M Friedman; Anna Lehman; Colin J Ross; Wyeth W Wasserman
Journal:  Neurogenetics       Date:  2021-07-02       Impact factor: 2.660

Review 10.  Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders.

Authors:  J Ng; S J R Heales; M A Kurian
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.